Flyte Aviation, Inc.
VJET Healthcare Medical Devices
Flyte Aviation, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $819,000.00, up 95.0% from fiscal 2024. In the quarter to June 2026, revenue grew 380.7%, EPS grew 87.3%, free cash flow fell 26.7% and total debt rose 160.0%, each against the same quarter a year earlier. Operating cash flow growth for five consecutive years.
Follow VJET
Flyte Aviation, Inc. (VJET) EV/Sales
As of 16 October 2026, Flyte Aviation, Inc. (VJET) trades at a EV/Sales of 2.1×. Over the past ten years it has ranged from −222× (June 2021) to 51,900,262× (October 2018); the current reading is higher than 10% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 28.1× | (13.43%) |
| FY2024 | 32.5× | (23.44%) |
| FY2023 | 42.4× | (98.42%) |
| FY2022 | 2,679× | (32.26%) |
| FY2021 | 3,954× | 759.79% |
| FY2020 | 460× | 1,288.95% |
| FY2019 | 33.1× | (100.00%) |
| FY2018 | 27,852,625× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 13.2× | (42.00%) |
| Mar 2026 | 22.7× | (19.20%) |
| Dec 2025 | 28.1× | (37.39%) |
| Sep 2025 | 44.9× | (15.33%) |
| 30 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NUVOQ Holdco Nuvo Group D.G Ltd. compare | n/m |
| NUWE Nuwellis, Inc. compare | 0.0× |
| DHAI DIH Holding US, Inc. compare | 0.1× |
| BIOLQ Biolase, Inc. compare | 0.3× |
| AFIB Acutus Medical, Inc. compare | 0.9× |
| XAIR Beyond Air, Inc. compare | 1.1× |
| VJET Flyte Aviation, Inc. | 2.1× |
| NXL Nexalin Technology, Inc. compare | 3.0× |
| ADGM Adagio Medical Holdings, Inc. compare | 32.1× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)